- Case report
- Open Access
Combined endocrine and exocrine tumours of the pancreas
© Alzaraa et al; licensee BioMed Central Ltd. 2007
- Received: 04 May 2007
- Accepted: 14 September 2007
- Published: 14 September 2007
Cystic neoplasms of the pancreas comprise 10%–15% of pancreatic cystic lesions, with the serous cystadenoms being the commonest. The association of exocrine and endocrine tumours of the pancreas unrelated to Von Hipple Lindau disease is very rare. Very few cases have been reported in the literature. We present another case of both these tumours in one patient.
A female patient was seen in the surgical clinic for a pain in the right groin. Clinical examination and investigations confirmed a diagnosis of combined endocrine and exocrine tumours of the pancreas. She underwent surgery and is under regular follow-up in the surgical clinic.
Biphasic differentiation of pancreatic stem cell during embryological development could happen and may result in combined endocrine and exocrine tumours of the pancreas. Imaging studies are excellent in diagnosing theses lesions. Surgery has a central role and could be curative.
- Cystic Lesion
- Endocrine Tumour
- Splenic Hilum
- Serous Cystadenoma
A 73 years-old lady was seen in the clinic in August 2006 for a right inguinal pain which had been present for a few months. She had no significant past medical history. Abdominal examination revealed a mass in the left upper quadrant. There were no other physical findings.
The patient has not shown any sings of recurrence and is under regular follow-up in the surgical clinic.
Cystic neplasms comprise 10%–15% of pancreatic exocrine lesions . They include a spectrum of benign, malignant and borderline neoplasms, of which, serous cystadenomas are most frequent. Pancreatic Endocrine Tumours (PETs) are rare (1 per 100,000 population), thought to originate from immature stem cells that are part of the neuroendocrine system. They are classified into functioning (70% of cases) if responsible for a clinical syndrome related to hormonal release, or non-functioning (15–30% of cases) if there are no hormone related symptoms  and may cause obstructive symptoms of the biliary tract, duodenum, gastrointestinal bleeding or abdominal mass. The commonest PETs are insulinomas and gastrinomas. The correlation between the morphological features and the clinical behaviour of PET is poor, and only the existence of metastatic disease indicates malignancy [5, 6]. Virtually always PETs are treated surgically as they have significant malignant potential , and if the symptoms are not controlled, chemotherapy may be tried but response is limited. The coexistence of pancreatic exocrine and endocrine tumours is very rare. The first case was described by Keel et al in 1996 . Embryologically, endocrine and exocrine pancreas develop from the endodermal lining of the duodenum, therefore, the potential of pancreatic ductal stem cells for biphasic differentiation along either glandular epithelial or neuroendocrine pathways is not unexpected [5, 6]. Indeed, biphasic differentiation is observed in many different pancreatic disorders, both benign and malignant, and can happen in two patterns. The first pattern of mixed differentiation produces tumours showing a combination of PET-like features and features of either ductal or acinar cell. The second pattern is manifested by the concurrent development of distinct epithelial and neuroendocrine cells within the same tumour .
Cystic neoplasms are a heterogeneous group of tumours with a real problem regarding differential diagnosis between neoplastic and inflammatory lesions owing to the similarities in the clinical presentations and in the characteristics visualized in imaging studies [1, 3, 4]. The WHO classification of exocrine tumours of the pancreas is based on the histopathological features of the epithelial wall, which are the main factor in the differential diagnosis with cystic lesions of the pancreas .
Women in their 50s seem to be the population most affected by both endocrine and exocrine tumours and any portion of the pancreas can be involved, but they are most frequently detected in the pancreatic head [4, 7]. The association of endocrine pancreatic tumour with cystadenomas is already known in patients with Von Hipple Lindau (VHL) disease, but the same association unrelated to VHL is quite rare, but not exceptional. In VHL, the pancreas is involved in up to 77% of patients, 12.3% serous cystadenomas, 12.3% by endocrine tumours and in 11.5% by combined lesions .
Clinically, cystic neoplasms are slow growing with no relevant symptoms or signs. When clinical sings are present, they may help pinpoint the organ of origin but never the type of pathology. Abdominal discomfort is the most common symptom. Weight loss, palpable mass, jaundice and obstruction of the upper gastrointestinal tract are rare and may be correlated to an extensive growth of the lesion . More than 1/3 of these lesions are incidentally detected by abdominal ultrasound or CT scan performed for the evaluation of other condition [1, 3, 4]. Very little information is available on the growth rate of serous cystadenomas and on the likelihood of these lesions .
CT and Magnetic Resonance Imaging(MRI) are excellent tests for cystic lesions of the pancreas, not only for the initial detection of a lesion but also for the characterization of such lesions by visualization of the calcification of the cyst wall, septa, mural nodules, possible showing of communication between a cyst and the pancreatic duct, and findings suggestive of pancreatitis. The presence of a central scar visualized with the use of CT or MRI is a highly diagnostic feature that is found in about 20% of serous cystadenomas .
Management of these lesions has not been standardised, is evolving and depends on many factors such as the presence or absence of symptoms, surgical risk of the patient, age, type of the tumour, its location and size. The proper evaluation and subsequent management of this disease in patients without symptoms have not been fully defined [1, 3]. The role of surgery is central because it could be curative when complete resection is possible . PET arising in association with a serous cystadenoma may reinforce the recommendation for surgical therapy of cystic tumours of the pancreas as mixed tumours may be present . The current death rate among patients undergoing pancreatic resection in specialized centres is less than 2% .
Combined endocrine and exocrine tumours of the pancreas are very rare. The potential of pancreatic ductal stem cells for biphasic differentiation along the embryologic developmental line of exocrine and endocrine pancreas could happen. Cystic lesions of the pancreas are asymptomatic and mainly discovered incidentally. Imaging studies such as CT and MRI are excellent tests which help diagnose these lesions. The role of surgery is central in managing these tumours, especially if both endocrine and exocrine tumours coexist, and could be curative if complete resection is performed.
A written consent was obtained from the patient for the publication of this report.
- Blandamura S, Parenti A, Famengo B, Canesso A, Moschino P, Pasquali C, Pizzi S, Guzzardo V, Ninfo V: Three cases of pancreatic serous cystadenoma and endocrine tumour. J Clin Pathol. 2007, 60: 278-282. 10.1136/jcp.2006.036954.PubMed CentralView ArticlePubMedGoogle Scholar
- Friebe v, Keck T, Mattern D, Schmitt-Graeff A, Werner M, Mikami Y, Adam U, Theodor Hopt u: Serous cystadenoma of the pancreas. Pancreas. 2005, 31: 182-187. 10.1097/01.mpa.0000167001.89018.3c.View ArticlePubMedGoogle Scholar
- Brugge M, Lauwers G, Sahani D, Castillo C, Warshaw A: Cystic neoplasms of the pancreas. N Engl J Med. 2004, 351: 1218-1226. 10.1056/NEJMra031623.View ArticlePubMedGoogle Scholar
- Salvia R, Festa I, Butturini G, Tonsi A, Sartori N, Biasutti C, Capelli P, Pederzoli P: Pancreatic cystic tumours. Minerva Chir. 2004, 59: 185-207.PubMedGoogle Scholar
- Keel , Suzanne B, Zukerberg , Laurence , Graeme-Cook , Fiona , Compton , Carolyn : A pancreatic endocrine tumour arising within a serous cystadenoma of the pancreas. Am J Surg Patho. 1996, 20: 471-475. 10.1097/00000478-199604000-00010.View ArticleGoogle Scholar
- Ustun MO, Tugyan N, Tunakan M: Coexistence of an endocrine tumour in a serous cystadenoma (microcytic adenoma) of the pancreas, an unusual association. J Clin Pathol. 2000, 53: 800-802. 10.1136/jcp.53.10.800.PubMed CentralView ArticlePubMedGoogle Scholar
- Jani N, Khalid A, McGrath K: Pancreatic endocrine tumours. VHJOE. 2004, 3: [last accessed on September 4, 2007],http://www.vhjoe.org/Volume3Issue3/3-3-2.htmGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.